Skip to content
AnalystLens

Idex 8-K Report, Financial Results (Apr 24, 2024)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed April 24, 2024
Period End
April 23, 2024
Security
IEX
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed April 24, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation reported first-quarter 2024 results for the period ended March 31, 2024, with net sales of $800.5 milliona, down 5% overall and down 6% on an organic basis, which the filing describes as in line with expectations.

Reported diluted EPS was $1.60b versus $1.84 a year earlier, and adjusted diluted EPS was $1.88 versus $2.09, which the company says exceeded first-quarter expectations. Operating cash flow was $156.6 million and free cash flow was $136.6 million, up 15.3 million from the prior-year period, and the company reduced its net debt position through strong cash generation, with cash and cash equivalents rising to $616.3 million at quarter-end. By segment, Fluid & Metering Technologies (FMT) sales were $313.7 million and adjusted EBITDA margin improved to 33.6%, Fire & Safety/Diversified Products (FSDP) sales rose 2% organically to $178.0 million with margin expanding to 28.9%, and Health & Science Technologies (HST) sales fell 13% organically to $310.1 million with adjusted EBITDA margin declining 250 bps to 26.2%.

Management cited an encouraging sequential lift in orders from core industrial and municipal markets, while noting uneven recovery across HST's targeted end markets. IDEX confirmed its full-year 2024 guidance, projecting organic sales growth of 0% to 2%, GAAP diluted EPS of $7.13 to $7.43c, and adjusted diluted EPS of $8.15 to $8.45. For the second quarter, it projects organic sales declines of 2% to 3% and adjusted diluted EPS of $2.00 to $2.05.

Key Highlights

  1. Net sales of $800.5 million, down 5% overall and 6% organically, versus $845.4 million in the first quarter of 2023; management described results as in line with expectations.
  2. Reported diluted EPS of $1.60 (down from $1.84) and adjusted diluted EPS of $1.88 (down from $2.09), which the company said exceeded first-quarter expectations.
  3. Operating cash flow of $156.6 million (up from $147.9 million) and free cash flow of $136.6 million (up from $121.3 million).
  4. Adjusted EBITDA of $208.3 million with an adjusted EBITDA margin of 26.0%, down 120 bps from 27.2%.
  5. Health & Science Technologies organic net sales fell 13%, with adjusted EBITDA margin down 250 bps to 26.2%, driven by lower volumes in analytical instrumentation, life sciences and semiconductor markets.
  6. Fluid & Metering Technologies adjusted EBITDA margin rose 60 bps to 33.6%, and Fire & Safety/Diversified Products organic sales rose 2% with adjusted EBITDA margin up 40 bps to 28.9%.
  7. Full-year 2024 guidance confirmed: organic sales growth of 0% to 2%, GAAP diluted EPS of $7.13 to $7.43, and adjusted diluted EPS of $8.15 to $8.45.

Frequently Asked Questions

  1. How did IDEX perform in the first quarter of 2024?

    IDEX reported net sales of $800.5 million, down 5% from $845.4 million a year earlier and down 6% on an organic basis, primarily due to lower volumes in the Health & Science Technologies segment. Reported diluted EPS was $1.60 versus $1.84, and adjusted diluted EPS was $1.88 versus $2.09. The company said results were in line with its sales expectations and that adjusted EPS exceeded its first-quarter expectations.

  2. What is the company's full-year 2024 outlook?

    IDEX confirmed full-year 2024 guidance projecting organic sales growth of 0% to 2%, GAAP diluted EPS of $7.13 to $7.43, and adjusted diluted EPS of $8.15 to $8.45. Estimated full-year adjusted EBITDA is $918.0 million to $947.9 million on net sales of $3,320.3 million to $3,385.6 million.

  3. What is the second-quarter 2024 outlook?

    For the second quarter of 2024, IDEX projects organic sales to decline 2% to 3% versus the prior-year period, GAAP diluted EPS of $1.75 to $1.80, and adjusted diluted EPS of $2.00 to $2.05.

  4. Which segment drove the decline in sales?

    The Health & Science Technologies segment drove the decline, with net sales of $310.1 million, down 13% organically. The company attributed this to lower volumes in analytical instrumentation, life sciences and semiconductor markets, largely due to inventory recalibration and market slowness carried over from 2023. Fluid & Metering Technologies sales were $313.7 million, down 3% organically.

  5. How strong was cash generation in the quarter?

    Operating cash flow was $156.6 million, up from $147.9 million, and free cash flow was $136.6 million, up from $121.3 million. Cash and cash equivalents rose to $616.3 million at March 31, 2024, from $534.3 million at December 31, 2023.